← FDA DRUG APPROVALS

FDA ANDA · ANDA202825

SERTRALINE HYDROCHLORIDE

Sponsor: ACCORD HLTHCARE

APPLICATION
ANDA202825
TYPE
ANDA
ORIGINAL APPROVAL
2014-11-07
LATEST ACTION
2024-11-07
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

SERTRALINE HYDROCHLORIDEPrescription
SERTRALINE HYDROCHLORIDE EQ 100MG BASE · TABLET · ORAL
SERTRALINE HYDROCHLORIDEPrescription
SERTRALINE HYDROCHLORIDE EQ 25MG BASE · TABLET · ORAL
SERTRALINE HYDROCHLORIDEPrescription
SERTRALINE HYDROCHLORIDE EQ 50MG BASE · TABLET · ORAL

Approval history

2024-11-07Labeling · Supplement 11 · standardAP
2024-11-07Labeling · Supplement 12 · standardAP
2024-11-07Labeling · Supplement 10 · standardAP
2018-05-08Labeling · Supplement 2 · standardAP
2018-05-08Labeling · Supplement 1 · standardAP
2014-11-07UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →